The 2-dose treatment regimen was superior to the 5-dose treatment regimen in the capacity of eMSCs-IL10 to suppress the expansion of CD4+ and CD8+ T cells and to reduce pro-inflammatory cytokine production in the GvHD mouse model. Here, CD8A is linked to graft versus host disease.